Fengcheng Meditech’s New R&D Center Commences Operations in TEDA

Recently, a brand new research and development center of Fengcheng Meditech (Tianjin) Co., Ltd. officially commenced operations in TEDA’s Binhai-Zhongguancun Science Park. This project occupies a floor area of nearly 3,000 square meters and includes facilities such as an organic synthesis standard lab, a small nucleic acid lab, a continuous reaction lab, a process amplification lab, and an analytical testing center. It is equipped with internationally advanced laboratory devices. The center will provide Contract Development and Manufacturing Organization (CDMO) services for clients, synthesis technology upgrades for catalog compound products, and the development and application of green chemistry technology. Furthermore, building on the company’s existing small molecule business, Fengcheng Meditech R&D Center will also develop techniques for modifying and preparing nucleoside monomers, thereby enhancing the company’s independent innovation capabilities and contributing to the high-quality development of the healthcare industry in the Binhai-Zhongguancun Science Park.

Fengcheng Group was founded in 2010 and is dedicated to providing customized R&D and production services covering the entire process from pre-clinical research to commercialization for global pharmaceutical and biotechnology companies. In 2022, Fengcheng Group established Fengcheng Meditech (Tianjin) Co., Ltd. in the Binhai-Zhongguancun Science Park, where the company takes on the function of the group’s research and development center.